Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
December 8, 2015
Baltimore biopharm hires neuroscience veteran Mohs as VP
Baltimore-based biopharmaceutical company AgeneBio has appointed Richard Mohs as vice president of clinical development. Mohs has more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab and semagacesta, AgeneBio noted in a statement Tuesday.
